AIMLogo.jpg
AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update
15. November 2024 07:29 ET | AIM ImmunoTech Inc.
– Continued execution across Ampligen® clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space – Driving significant momentum with...
fortressbio1.jpg
Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
14. November 2024 16:10 ET | Fortress Biotech, Inc.
Emrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adults Cosibelimab PDUFA goal date of December 28 for potential approval to treat metastatic or locally...
60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results
14. November 2024 14:31 ET | Sixty Degrees Pharmaceuticals
60 Degrees Pharma (SXTP) reported 164% revenue growth and clinical progress on ARAKODA® for infectious diseases and babesiosis in its 3Q24 earnings report.
PharmAla Biotech Logo 800 x 422.png
PharmAla Reaches Agreement in Principle to Supply MDMA to Clinical Trial in Exchange for Full Data License
14. November 2024 09:20 ET | PharmAla Biotech
PharmAla reaches agreement in principle to trade with a clinical trial to trade its LaNeo MDMA for a data license to the trial outcomes.
Logo_AdipoPharma_V1.png
French Biotech Company AdipoPharma Secures Funding to Initiate Clinical Trials for its first-in-class compound for Insulin Resistance
11. November 2024 12:43 ET | AdipoPharma
STRASBOURG, France, Nov. 11, 2024 (GLOBE NEWSWIRE) -- AdipoPharma, a biotech company headquartered in France with offices in the US and Belgium developing a novel and promising Type 2 diabetes drug,...
PharmAla Biotech Logo 800 x 422.png
PharmAla to supply LaNeo MDMA for Clinical Trial at Yale
07. November 2024 09:20 ET | PharmAla Biotech
PharmAla to supply Yale University with MDMA for clinical trial
22157.jpg
Zollinger-Ellison Syndrome (Gastrinoma) Global Clinical Trials Review 2024: Country (G7 & E7), Phase, Trial Status, End Points Status and Sponsor Type
06. November 2024 08:56 ET | Research and Markets
Dublin, Nov. 06, 2024 (GLOBE NEWSWIRE) -- The "Zollinger-Ellison Syndrome (Gastrinoma) - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. ...
QUOIN-COLORED-LOGO (1).png
Quoin Pharmaceuticals Initiates Clinical Testing of Lead Product in Pediatric Netherton Syndrome Patient
05. November 2024 08:00 ET | Quoin Pharmaceuticals, Inc.
Clinical Assessment Is Being Performed on a Pediatric Patient at Children’s Health Ireland in Dublin First Evaluation of QRX003 in a Pediatric Patient Second Clinical Site to Open in Spain with...
NAYA_Biosciences_Logo.jpg
NAYA Biosciences to Present Translational Insights to Support Phase I/IIa Clinical Trials for its GPC3-Targeting NK Engager Bispecific Antibody at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
31. Oktober 2024 09:00 ET | NAYA Biosciences, Inc.
SARASOTA, Fla. and MIAMI, Oct. 31, 2024 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in...
h1-logo-main (1).png
H1 Expands Trial Landscape with U.K. Diversity Data to Enhance Clinical Trial Equity and Meet Evolving Regulatory Standards
30. Oktober 2024 09:00 ET | H1
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- H1, on a mission to connect the world to the right doctors, today announced that diversity data and insights on 34 million patients being treated within...